

## CURRICULUM VITAE

**Name** TIIHONEN, Arto Jari Tapani

**Date and place of birth** 27 Nov 1960 Säyneinen, Finland

**ORCID** 0000-0002-0400-6798

**Researcher ID** G-3078-2012

**H-index** 70 (November 22, 2021, Scopus)

**Contact details** Jari Tiihonen  
Karolinska Institutet  
Department of Clinical Neuroscience  
Norra Stationsgatan 69,  
11364 Stockholm, Sweden  
jari.tiihonen@ki.se

### Current position

Professor, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden	since 1 Sep 2011
Part-time Chief Psychiatrist Psykiatri Nordväst, Stockholm, Sweden	since 1 Sep 2011
Professor and Chairman, Department of Forensic Psychiatry, University of Eastern Finland, Kuopio, Finland	since 1 Aug 2003
Part-time Chief Psychiatrist Niuvanniemi Hospital, Kuopio, Finland	since 1 Aug 2003
Visiting Researcher Neuroscience Center, University of Helsinki	since 1 Oct 2020

### Education and training

Licentiate of Medicine, University of Kuopio	21 Aug 1985
Doctor of Medical Sciences, University of Kuopio Topic: Evoked and spontaneous neuromagnetic activity in man.	31 Jan 1990
Docent (Senior Lecturer) in Neurophysiology, University of Kuopio	25 May 1992
Specialist in Psychiatry, University of Kuopio	21 Feb 1994
Specialist in Forensic Psychiatry, University of Kuopio	20 Dec 1994
Docent (Senior Lecturer) in Psychiatry, University of Helsinki	1 Oct 2003

### Previous professional appointments

Resident Physician in Departments of Psychiatry, Kuopio University Hospital, Niuvanniemi Hospital, and Outpatient Care of Psychiatric District of Harjamäki Hospital; total 4 years	1985–1993
Resident Physician in Department of Clinical Neurophysiology, Kuopio University Hospital, Vaajasalo Epilepsy Hospital; total 1 year 3 months	1986–1990
Junior Research Fellow, Low Temperature Laboratory, Helsinki University of Technology; total 2 years	1987–1989
Senior Lecturer in Neurophysiology, University of Kuopio; total 4 years	1992–1996
Senior Psychiatrist, Niuvanniemi Hospital; total 11 months	1993–1994
Chief Psychiatrist, Niuvanniemi Hospital; total 4 months	1994
Associate Professor, Department of Psychiatry, Oulu University Hospital; total 2 months	1995
Part time Chief Psychiatrist, Oulu University Hospital; total 2 months	1995
Professor and Chairman, Department of Forensic Psychiatry, University of Kuopio; total 6 years 2 months	1995–2001

Part-time Chief Psychiatrist, Niuvanniemi Hospital; total 6 years and 2 months	1995–2001
Medical Director, Niuvanniemi Hospital (284 beds, 470 employees); total 13 months	1998–1999
Chief Psychiatrist, Helsinki University Central Hospital HUCH, Lapinlahti Hospital; total 2 years 3 months	2001–2003
Professor and Chairman, Department of Psychiatry, University of Helsinki; total 2 years 3 months	2001–2003
Part-time Research Professor, National Institute for Health and Welfare, Helsinki; total 7 years 3 months	2008–2015

### **Research awards, honours and major grants**

Scholarship for clinical aggression research (FIM 45000, University of Kuopio)	1992
Scholarship for alcohol research (FIM 80000, Finnish Alcohol Research Foundation)	1993
Schizophrenia Research Award (FIM 10000, Sandoz)	1993
Martti Hämmäläinen Award (FIM 10000, The Medical Society of Northern Savo)	1993
Scholarship for schizophrenia research (FIM 75000, University of Kuopio)	1994
Research Funding to the Department of Forensic Psychiatry/Niuvanniemi Hospital (FIM 10377400, Ministry of Health and Welfare)	1995–2000
The title of Primus Doctoralis at The Fourth Solemn Conferment Ceremony, University of Kuopio	1996
Scholarship for alcohol research (FIM 45000, University of Kuopio)	1996
Lundbeck Award (FIM 10000, Oy H Lundbeck Ab)	1996
Scholarship for alcohol research (FIM 45000, University of Kuopio)	1997
Lapinlahti award (FIM 2000, Lapinlahti Hospital)	1998
Lapinlahti medal (Lapinlahti Hospital)	1998
1998 Michell B. Balter Award (Journal of Clinical Psychopharmacology)	1999
Niuva award (EUR 1700, Janssen-Cilag)	2002
Grant for treatment trial (USD 67840, Stanley Foundation)	2002
Special subsidies (Research funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 1266361, Ministry of Health and Welfare)	2004–2009
18 <sup>th</sup> ECNP Congress, Amsterdam, The Netherlands Poster Award “Effectiveness of antipsychotic treatments in first-episode schizophrenia”	2005
Grant for research on panic disorder (EUR 28600, Yrjö and Tuulikki Ilvonen Fund)	2006
The best publication of psychiatry research in Finland in year 2005 (ref. no. 161 in the list of publications) (Finnish Psychiatric Association)	2006
Grant for pharmacoepidemiological research (EUR 25000, University of Kuopio)	2006
Grant for HUUTI consortium, PI Jari Tiihonen (EUR 244590, Academy of Finland)	2007–2009
Grant for conducting randomized clinical trials in substance abuse [EUR 75000, National Research and Development Centre for Welfare and Health (STAKES)]	2007
The best publication of psychiatry research in Finland in year 2009 (ref. no. 205 in the list of publications) (Finnish Psychiatric Association)	2010
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 337012, Ministry of Health and Welfare)	2010
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 376651, Ministry of Health and Welfare)	2011
Grant for treatment trial (USD 306572, 12TAF-1635, Stanley Foundation)	2012
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 513709, Ministry of Health and Welfare)	2012
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 331300, Ministry of Health and Welfare)	2013
The best publication of psychiatry research in Finland in year 2012 (ref. no. 233 in the list of publications) (Finnish Psychiatric Association)	2013
The Ronald D. Mann Best Article Award, Pharmacoepidemiology and Drug Safety, the best article published in 2012 (ref. no 240 in the list of publications)	2013
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 254251, Ministry of Health and Welfare)	2014
State Research Funding for stem cell research (EUR 62500, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2014–2015
Grant for stem cell research (EUR 55000, Sigrid Jusélius Foundation; co-applicant Jari Koistinaho)	2014–2015

Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 310 651, Ministry of Health and Welfare)	2015
State Research Funding for stem cell research (EUR 59787, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2015–2016
Grant for register-based study “A nationwide cohort study of oral and depot antipsychotics” (Eli Lilly, USD 100400)	2015–2017
Grant for register-based study “The antipsychotics broad based assessment (ABBA)” (Janssen-Cilag, SEK 2130238)	2015–2017
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 464702, Ministry of Health and Welfare)	2016
Grant for “Work disability and mortality related to ischemic heart disease – the role of psychiatric comorbidity” (SEK 3 million, Swedish Research Council; as a co-applicant, main applicant Marjan Vaez)	2016–2018
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 350471, Ministry of Health and Welfare)	2017
State Research Funding for register-based study (EUR 68450, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2017
Grant for “Pathways to granted disability pension in young adults with common mental disorders” (SEK 1280000, Karolinska Institutet, KID funding; as a co-applicant, main applicant Ellenor Mittendorfer-Rutz)	2017–2020
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 308666, Ministry of Health and Welfare)	2018
State Research Funding for register-based study (EUR 77642, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2018
Congress Award for the best poster and communication, L’Encéphale Congress, January 24–26, 2018, Paris, France, “Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients”.	2018
Grant for register-based study (EUR 34805, The Social Insurance Institution of Finland)	2018–2020
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; 394887, Ministry of Health and Welfare)	2019
State Research Funding for register-based study (EUR 117375, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2019
Grant for register-based study/Trifi (EUR 46226, Janssen-Cilag)	2019–2021
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 465039, Ministry of Health and Welfare)	2020
State Research Funding for register-based study (EUR 100000, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2020
Special subsidies (Research Funding to the Department of Forensic Psychiatry/ Niuvanniemi Hospital; EUR 755480, Ministry of Health and Welfare)	2021
State Research Funding for register-based study (EUR 75000, Research Committee of the Catchment Area of the Hospital District of Northern Savo, State Research Funding)	2021

### **Memberships in scientific societies**

Member of Duodecim (Finnish College of Physicians)	1983–
President of the Finnish Psychopharmacological Association	2001–2003
Member of the European College of Neurophychopharmacology (ECNP)	2002–2013
Member of Society for Neuroscience	2004–2012
Member of the International Society for Affective Disorders	2004–
Member of Society of Biological Psychiatry	2005–
Member of Schizophrenia International Research Society (SIRS)	2006–
Fellow Member of European College of Neuropsychopharmacology (ECNP)	2013–
Member of American College of Neuropsychopharmacology (ACNP)	2015–

### Other academic and professional activities

Referee for doctoral dissertation (for ten different theses)	1995–
Member of the working party that develops regulations of state mental hospitals (Working Group Memorandum of the Ministry of Social Affairs and Health 1996:14)	1996
Opponent for doctoral dissertation (for four dissertations) (Helsinki 1996, Trondheim 2001, Turku 2006, Helsinki 2008)	1996–
Supervised doctoral dissertation (for 27 different theses)	1997–
Member of the Hospital Board of Niuvanniemi Hospital	1997–2001
Faculty Member of the Lundbeck International Neuroscience Foundation	1997–2007
Member of Faculty Board of the Faculty of Medicine, University of Kuopio	1998–2001
Deputy member of Hospital Board of Kuopio University Hospital	1998–2001
Member of International Editorial Board (Journal of Forensic Medicine and Toxicology)	1998–
Member of the working party that develops involuntary psychiatric treatment for juveniles (Working Group Memorandum of the Ministry of Social Affairs and Health 2000:7)	1999–2000
Member of the working party that develops medical treatments for opioid-dependent persons (Working Group Memorandum of the Ministry of Social Affairs and Health 2001:21)	2000–2001
Member of the Hospital Board of Niuvanniemi Hospital	2002–
Member of Global Advisory Board on Substance Abuse, BMS	2002–2004
Member of Faculty Board of the Faculty of Medicine, University of Kuopio	2004–2009
Member of Executive Committee of Foundation of Alcohol Research, Ministry of Education	2004–2010
Expert Member of National Authority of Medicolegal Affairs	2004–2012
Deputy member of Board of Brain Research Center, University of Kuopio	2004–2010
Member of the working party “Consolidation of the Penal Code and the Mental Health Act. Provisions on criminal patients” (Working Group Memorandum of the Ministry of Social Affairs and Health 2005:20)	2004–2005
Member of the Scientific Committee of Finnish Office for Health Technology Assessment (FinOHTA)	2005–2007
Referee for docent applications (for 14 different docents)	2006–
Consult/Expert Member of Advisory Board of Janssen-Cilag	2006–
Board member of AEP Core Organizing Scientific Committee	2006–2009
Member of Advisory Board for Framingham on Bipolar Disorders and Schizophrenia	2007–
Member of International Editorial Board (The Open Law Journal)	2007–
Member of the Editorial Board (The World Journal of Biological Psychiatry)	2009–
Member of the management group “Preclinical animal models of neuro-psychiatric symptoms – extension of CNS expertise in Kuopio region”	2010–2014
Member of the scientific board “Preclinical animal models of neuropsychiatric symptoms – extension of CNS expertise in Kuopio region”	2010–2014
Member of the Editorial Board (The World Journal of Psychiatry)	2011–2012
Member of the ECNP Award Committee	2011–
Member of Advisory Board of Otsuka	2013–
Member of SIRS (Schizophrenia International Research Society) Program Committee	2014–2016
Member of Advisory Board of Evidence-Based Psychiatric Care	2014–
Scientific Committee member of 11 <sup>th</sup> Nordic Symposium on Forensic Psychiatry	2014–2015
Member in review committee for evaluation of research applications in the South-East Norway Regional Health Authority	2014–2016
Reviewer of research application in The Health Research Board, Ireland	2017
Member of EPA (European Psychiatrist Association) Program Committee	2020–2021
Scientific Committee member of 12 <sup>th</sup> Nordic Symposium on Forensic Psychiatry	2020–2022

### Invited lectures

- ESCAP-symposium on forensic psychiatry. September 20, 1995, Utrecht, Holland. “Altered serotonin re-uptake site densities associated with impulsive violent behaviour.”
- American Association for the Advancement of Science. February 8-13, 1996, Baltimore, Maryland, USA. Session: Major Mental Disorders and Crime: New Data, New Policies? “Schizophrenia and homicide”.

- Skandinavisk Selskap for Psykofarmakologi. 37. Årsmøde. April 24-26, 1996, København, Danmark. The Plenary Lecture: "Biology and pharmacology of violence and impulse control."
- The Royal Society of Medicine and the Swedish Society of Medicine. Brooke Lecture: "Violence as a public health issue". Berzelius Symposium. October 24-25, 1996, London, England. "Mental illness and violence."
- Lapinlahti-päivät. August 8, 1998, Helsinki, Finland. "Hyvyys, pahuus ja vapaa tahto" (in Finnish).
- NATO Advanced Study Institute. Effective Prevention of Crime and Violence among Persons with Major Mental Disorders. May 16-26, 1999, Tuscany, Italy. "Pharmacological intervention for preventing violence among the mentally ill with secondary alcohol and drug use disorders".
- V World Congress of Depressive Disorders, September 25 – 27, 2003, Mendoza, Argentina. "Premorbid intellectual functioning in bipolar disorder".
- V World Congress of Depressive Disorders, September 25 – 27, 2003, Mendoza, Argentina. "Dopamine synthesis in major depression".
- Paolo Foundation Symposium 2004: Effectiveness Research in Psychiatry, 27–28 May, Lahti, Finland. "Real-world effectiveness research by using national computer-based registers".
- XXIVth CINP Congress, June 20–24, 2004, Paris, France. "Glutamatergic mechanisms in the etiology and treatment of schizophrenia: Focus on the ionotropic NMDA receptors".
- 17<sup>th</sup> ENCP Congress, GSK Lamictal symposium, 9–13 October 2004, Stockholm, Sweden. "Beyond bipolar depression: New developments in the spectrum of psychiatric disorders."
- Invited lecture, McGill University, Department of Psychiatry, Montréal, Canada, April 15, 2005. "Real-world effectiveness of antipsychotic treatments in first-episode schizophrenia".
- The 6<sup>th</sup> Nordic Symposium on Forensic Psychiatry, August 24–26, 2005, Vaasa. "Effectiveness of pharmacological treatment of schizophrenia".
- 18<sup>th</sup> ECNP Congress, Amsterdam, The Netherlands, October 22–26, 2005. "Effectiveness of antipsychotic treatments in first-episode schizophrenia" (an oral presentation of the Awarded Poster).
- NIDA ACNP satellite symposium, Hilton Waikoloa Village, Hawaii, USA, December 11-15, 2005. "A comparison of aripiprazole, methylphenidate and placebo for amphetamine dependence".
- 19<sup>th</sup> ECNP Congress, Paris, France, September 16–20, 2006. "Antidepressant use and the risk of suicide, attempted suicide and overall mortality in a nation-wide cohort" (an oral presentation of the Breaking News).
- VIII ISAM Meeting, Oporto, Portugal, September 27–30, 2006. "Aripiprazole, methylphenidate and placebo of amphetamine dependence" (an oral presentation in a symposium "Pharmaceutical treatments for methamphetamine dependence – NIDA").
- Perspectives of pharmacoepidemiology in Finland and in Europe, Helsinki, 2<sup>nd</sup> November 2006. "Real-world effectiveness of antipsychotic treatments. Example of using nation-wide registers for pharmacoepidemiologic research".
- 7<sup>th</sup> Annual IAFMHS (International Association of Forensic Mental Health Services) Conference, June 26–28, 2007, Montreal, Canada. Plenary lecture: "Violent Behaviour: From Etiology to Interventions".
- 7<sup>th</sup> Nordic Forensic Psychiatric Symposium, Oslo, Norway, 22–24 August 2007. "On recidivistic violent behaviour".
- 20<sup>th</sup> ECNP Congress, Vienna, Austria, October 13–17, 2007. "Treatment discontinuation and rehospitalization: minimizing the risks".
- Neurobiologie Congres: Nieuw Kompas voor de Forensische Psychiatrie? Nijmegen, The Netherlands, January 17, 2008. "Violent behaviour: from etiology to interventions".
- 49<sup>th</sup> Annual Meeting of the SCNP (Scandinavian College of Neuro-Psychopharmacology). Juan-les-Pins, France, April 2–4, 2008. "Methylphenidate in the treatment of amphetamine dependence. "
- 22<sup>th</sup> ECNP Congress, 12–16 September 2009, Istanbul, Turkey. Highlights Live. "Schizophrenia".
- Asia Regional Neuroscience Conference, July 25–27, 2009, Narita, Japan. "Longterm effectiveness of antipsychotic treatments: an 11-year follow-up study of 66,881 patients".
- Latin American Informational Meeting, Santiago, Chile, 22–24 September 2010. "Risk and outcomes: The Finnish cohort papers".
- Brazilian Congress of Psychiatry, Fortaleza, Brazil, 28 October 2010. "Risk and outcomes: The Finnish cohort studies".
- II International Neuro-Psychopharmacotherapy Conference: Focus on treatment effectiveness in Psychiatry, 10–14 November 2010, Lanzarote, Canary Islands, Spain. "Long-term antipsychotic treatment: efficacy, safety and life expectancy considerations".
- 2<sup>nd</sup> Asian Congress on Schizophrenia Research, February 11–12, 2011, Seoul, Korea. "Long-term antipsychotic treatment: efficacy, safety and life expectancy considerations".

- 53<sup>rd</sup> Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology (SCNP), 25–27 April 2012, Copenhagen. “Augmentation strategies in schizophrenia: clinical outcomes”.
- Current Perspectives in Psychosis Research, September 6, 2012, Turku, Finland. “Why do we need register studies in psychiatric research?”
- The 10<sup>th</sup> Nordic Symposium on Forensic Psychiatry, August 21–23, 2013, Kuopio, Finland. “Psychopharmacology and violent offending”
- Fórum Janssen de Saúde Mental: Cruzando Fronteiras em Esquizofrenia, São Paulo, September 6<sup>th</sup>, 2013. “Real-world effectiveness of antipsychotic treatment in schizophrenia”.
- Suicide Prevention Day, Svenska Läkarsällskapet. September 10, 2013, Stockholm, Sweden. “Psychopharmacological aspects of suicide prevention in patients with schizophrenia”.
- 7<sup>th</sup> Annual Pacific Psychopharmacology Conference, September 20, 2013, Vancouver, Canada, Keynote lecture. “The effectiveness of interventions in treatment-resistant schizophrenia”.
- WPA 2013, Otsuka and Lundbeck sponsored symposium at WPA. Advances in schizophrenia: Can long-acting antipsychotics help protect what is important for patients? October 28, 2013, Vienna Austria. “The influence of clinical trial design on effects of long-acting injectable antipsychotics”.
- Seminaarisarja Rekisterit hoidon vaikuttavuuden ja potilasturvallisuuden tutkimuksessa, Itä-Suomen yliopisto 3.3.2014, Kuopio “Skitsofrenian lääkehoitojen vaikuttavuus”. [Seminar series Registers as a data source for effectiveness and patient safety research, University of Eastern Finland, March 3, 2014, Kuopio, Finland. “Effectiveness of pharmacological treatments in schizophrenia”]
- 23<sup>rd</sup> Congress of the International Academy of Legal Medicine, 19.–21 January 2015, Dubai, Arab Emirates, oral presentation “Psychotropic drugs and homicide: observational follow-up study”.
- Polish Psychiatric Society. The LAI treatment conference: Long-acting injectable antipsychotic medications, March 6–7, 2015, Warsaw, Poland. “What can we reach with LAI, that we cannot reach with oral antipsychotics?”
- Karolinska Institutet Discovers. March 18, 2015, Stockholm, Sweden. “Genetic background of extreme violent behaviour”.
- Psykiatrian alojen johtajien neuvottelupäivät, 11.–12.5.2015, Kuopio, Finland. ”Skitsofrenian farmakologisen hoidon toteutumisesta Suomessa ja Ruotsissa”.
- The 1<sup>st</sup> Finnish Symposium of Biological Psychiatry, 18.5.2015 Helsinki, Finland. “Genetic background of extreme violent behaviour”.
- The Baltic Conference of Psychiatry, 5<sup>th</sup> June 2015, Jurmala, Latvia “The real-world effectiveness of pharmacological treatment of schizophrenia”.
- 11<sup>th</sup> Nordic Symposium on Forensic Psychiatry, 26<sup>th</sup>–28<sup>th</sup> August, 2015, Trondheim, Norway “Genetic background of extreme violent behaviour”.
- Herman van Praag –lecture at UMC Utrecht (University Medical Center Utrecht), 25<sup>th</sup> January, 2016, Utrecht, The Netherlands, “The real-world effectiveness of pharmacological treatment of schizophrenia”.
- Skitsofrenian hyvä hoito tänään ja huomenna. 8.5.2017, Kuopio, Finland ”Skitsofrenian lääkehoidon vaikuttavuus”
- Open Mind Summit, 18<sup>th</sup>–19<sup>th</sup> August 2017, Sao Paulo, Brazil, “Real-world effectiveness of antipsychotic treatment”.
- VI International Forum of Schizophrenia, 23–24 November, 2017, Madrid, Spain, “Real-world effectiveness of antipsychotic treatment”.
- Regularly Scheduled Series at The Zucker Hillside Hospital, November 29<sup>th</sup> 2017, New York, “Real-world effectiveness of antipsychotic treatment”.
- Psychiatry Academy 2018, 11<sup>th</sup> January, 2018, Brugg, Switzerland, “Real-world effectiveness of antipsychotic treatments”.
- French National Congress of Psychiatry, L’Encéphale Congress, January 24–26, 2018, Paris, France, “Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29,823 patients”.
- Janssen sponsored satellite symposium at the 26<sup>th</sup> European Congress of Psychiatry (EPA 2018), 3.–6. March 2018, Nice, France, Reducing relapse and mortality in schizophrenia: myth or reality? “Mortality in schizophrenia: do we need to think about that now?”
- Svenska Psykiatrikongressen 2018, March 14–15, 2018, Stockholm, Sweden, “Real-world effectiveness of antipsychotic treatments”.
- 13<sup>th</sup> Annual Meeting of Japanese Society of Schizophrenia Research, 23–24 March 2018, Tokushima, Japan, “Real-world effectiveness of antipsychotic treatments in schizophrenia”. “
- 6<sup>th</sup> Biennial Schizophrenia International Research Society Conference (SIRS), 4–8 April 2018 Firenze, Italy, symposium “Reconsidering the Evidence for Clozapine for Treatment Refractory Schizophrenia”, presentation “What does epidemiological data tell us about clozapine’s effectiveness?”

- Nationell psykoskonferens, Göteborg, Sweden, 16–18 May 2018 “Real-world effectiveness of antipsychotic treatments in schizophrenia”.
- Suomen Psykiatripäivät, 1.11.2018, Helsinki, Finland. “Kun klotsapiini ei riitä – psykoosilääkkeiden kombinaatio- ja augmentaatiostrategioita”.
- American College of Neuropsychopharmacology (ACNP) 57th Annual Meeting, December 9–13, 2018, Hollywood, Florida, Study Group session The debate regarding maintenance treatment with antipsychotics in schizophrenia, “What is the optimal length of antipsychotic treatment to prevent relapse and death?”
- Current Approaches to Optimizing Care in Schizophrenia, Royal College of Physicians and Surgeons, September 27, 2019, Ottawa, Canada, “Real-world effectiveness of antipsychotic treatments in schizophrenia”.
- 28<sup>th</sup> European Congress of Psychiatry, 4–7 July 2020, Madrid, Spain, virtual meeting. Session Monotherapy against polypharmacy in schizophrenia: what is the evidence? “Are there specific antipsychotic combinations that are superior to monotherapies in the long-term treatment of schizophrenia?”
- 29<sup>th</sup> European Congress of Psychiatry, 10-13 April 2021, virtual meeting. “Effectiveness of antipsychotics in schizophrenia with comorbid substance use disorder”.
- 33<sup>rd</sup> Nordic Congress of Psychiatry, 17<sup>th</sup>–18<sup>th</sup> June 2021, virtual meeting, Satellite symposium Breaking Depression. “What can we learn from treatment resistant depression using national register data”.